SEC Stock Data Quick Answer Abacus Global Management, Inc. reported Total Revenue of $235.24 million for fiscal year 2025. Abacus Global Management, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $235.24M +110.2% 2024 $111.92M +68.6% 2023 $66.40M +48.5% 2022 $44.71M — Quarterly Total Revenue Quarter Ending Total Revenue YoY QoQ September 30, 2025 … Read more
Quick Answer Abacus Global Management, Inc. reported Total Revenue of $235.24 million for fiscal year 2025. Abacus Global Management, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $235.24M+110.2% $111.92M+68.6% $66.40M+48.5% $44.71M — — Net Income $36.53M+252.4% -$23.96M-351.8% $9.52M-70.0% $31.68M+100.0% $15.84M — Diluted EPS $0.36+205.9% -$0.34-312.5% $0.16-74.6% $0.63 — … Read more
Quick Answer ABVC BIOPHARMA, INC. reported Shares Outstanding of 25.05 million shares for fiscal year 2025. ABVC BIOPHARMA, INC. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 25.05M +80.6% 2024 13.87M +74.7% 2023 7.94M +141.6% 2022 3.29M -86.5% 2021 24.42M +0.0% 2020 24.42M +25.4% 2019 19.48M +63.9% 2018 11.88M -94.4% 2017 … Read more
Quick Answer ABVC BIOPHARMA, INC. reported Gross Profit of $508.8 thousand for fiscal year 2024. ABVC BIOPHARMA, INC. Gross Profit — Annual History Fiscal Year Gross Profit YoY Change 2024 $508.8K +440.1% 2023 -$149.6K -121.9% 2022 $683.4K +94.9% 2021 $350.7K -24.5% 2020 $464.3K -31.9% 2019 $681.6K +482.2% 2018 -$178.3K -557162.5% 2016 -$32.00 -101.1% 2015 $2.8K … Read more
Quick Answer ABVC BIOPHARMA, INC. reported Operating Income of -$7.15 million for fiscal year 2025. ABVC BIOPHARMA, INC. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$7.15M -52.0% 2024 -$4.71M +30.5% 2023 -$6.77M +55.2% 2022 -$15.11M -29.1% 2021 -$11.71M -37.6% 2020 -$8.51M -145.9% 2019 -$3.46M -24.2% 2018 -$2.78M +32.7% 2017 -$4.14M … Read more
Quick Answer ABVC BIOPHARMA, INC. reported R&D Expense of $121.1 thousand for fiscal year 2025. ABVC BIOPHARMA, INC. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $121.1K -32.5% 2024 $179.3K -83.1% 2023 $1.06M -60.5% 2022 $2.69M +168.3% 2021 $1.00M +82.6% 2020 $549.7K -47.6% 2019 $1.05M +6.1% 2018 $988.7K -68.8% 2017 $3.17M … Read more
Quick Answer ABVC BIOPHARMA, INC. reported Stockholders Equity of $11.11 million for fiscal year 2025. ABVC BIOPHARMA, INC. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $11.11M +806.2% 2024 $1.23M -21.1% 2023 $1.55M -49.8% 2022 $3.10M -65.0% 2021 $8.84M +157.2% 2020 $3.44M +2377.6% 2019 -$151.0K +97.3% 2018 -$5.66M -222.0% 2017 -$1.76M … Read more
Quick Answer ABVC BIOPHARMA, INC. reported Cash and Equivalents of $681.5 thousand for fiscal year 2025. ABVC BIOPHARMA, INC. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $681.5K +174.4% 2024 $248.4K +312.9% 2023 $60.2K -29.4% 2022 $85.3K -98.5% 2021 $5.83M +36.4% 2020 $4.27M +2861.4% 2019 $144.3K -36.3% 2018 $226.7K … Read more
Quick Answer ABVC BIOPHARMA, INC. reported Total Assets of $21.06 million for fiscal year 2025. ABVC BIOPHARMA, INC. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $21.06M +179.3% 2024 $7.54M -3.1% 2023 $7.78M -18.7% 2022 $9.58M -30.1% 2021 $13.70M +18.0% 2020 $11.61M +67.5% 2019 $6.93M +16.6% 2018 $5.94M +124.7% 2017 $2.64M … Read more
Quick Answer ABVC BIOPHARMA, INC. reported Diluted EPS of $0.39 per share (loss) for fiscal year 2025. ABVC BIOPHARMA, INC. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$0.39 +7.1% 2024 -$0.42 +76.7% 2023 -$1.80 +65.3% 2022 -$5.19 -917.6% 2021 -$0.51 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ … Read more